Free tool
FAERS Monitor: Abilify
Last checked: Nov 21, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021436 or its brand name (Abilify, Aripiprazole). Reports on generic versions are filed under their own applications.
Reports
117,169
Serious
79,602
68% of reports
Hospitalization
35,264
Death reported
6,592
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective8,220
- weight increased7,537
- off label use7,367
- anxiety5,051
- product use in unapproved indication4,908
- fatigue4,193
- suicidal ideation4,038
- nausea4,005
- depression3,968
- insomnia3,832
- drug interaction3,695
- tremor3,625
- suicide attempt3,567
- somnolence3,498
- condition aggravated3,196
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,521 |
| 2005 | 1,783 |
| 2006 | 927 |
| 2007 | 1,986 |
| 2008 | 1,061 |
| 2009 | 6,101 |
| 2010 | 2,518 |
| 2011 | 4,124 |
| 2012 | 4,193 |
| 2013 | 3,267 |
| 2014 | 6,448 |
| 2015 | 7,439 |
| 2016 | 7,002 |
| 2017 | 12,295 |
| 2018 | 9,454 |
| 2019 | 6,382 |
| 2020 | 6,054 |
| 2021 | 6,740 |
| 2022 | 5,661 |
| 2023 | 5,988 |
| 2024 | 6,012 |
| 2025 | 5,563 |
| 2026 | 4,646 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,936,990 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| suicidal ideationSignal | 4,038 | 8.2 | 8.0 | 24,645 |
| weight increasedSignal | 7,537 | 6.2 | 6.1 | 32,225 |
| drug interactionSignal | 3,695 | 4.3 | 4.1 | 9,058 |
| tremorSignal | 3,625 | 4.0 | 3.9 | 7,991 |
| product use in unapproved indicationSignal | 4,908 | 3.6 | 3.5 | 9,168 |
| anxietySignal | 5,051 | 3.2 | 3.1 | 7,720 |
| depressionSignal | 3,968 | 3.2 | 3.1 | 5,847 |
| insomniaSignal | 3,832 | 2.6 | 2.5 | 3,784 |
| condition aggravated | 3,196 | 1.9 | 1.8 | 1,359 |
| off label use | 7,367 | 1.5 | 1.5 | 1,332 |
| drug ineffective | 8,220 | 1.1 | 1.1 | 113 |
| fatigue | 4,193 | 1.0 | 0.9 | 5 |
| nausea | 4,005 | 0.9 | 0.9 | 39 |
| suicide attempt | 3,567 | 0.0 | 0.0 | 637,317 |
| somnolence | 3,498 | 0.0 | 0.0 | 624,984 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.